Skip to main content

Danahy Kevin Patrick's Form 4 filing

Pulse Biosciences, Inc. (PLSE) · filed Oct 3, 2022

Accession no.
0001839882-22-022698
Filed
Oct 3, 2022
Trade date
Sep 30, 2022
Filing delay
3 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction. Open-market purchases total $14.9K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Danahy Kevin PatrickCIK 0001913245Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 30, 2022Common StockPPurchaseAcquired+6,500$2.30F1+$14,9506,500Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This purchase price represents the weighted average purchase price of the shares purchased on September 30, 2022, ranging from $2.28 to $2.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)